76 related articles for article (PubMed ID: 15758780)
1. Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator (SARM), the 5alpha-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia (BPH).
Seftel A
J Urol; 2005 Apr; 173(4):1279. PubMed ID: 15758780
[No Abstract] [Full Text] [Related]
2. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
3. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
4. 5alpha-reductase isozymes and androgen actions in the prostate.
Zhu YS; Imperato-McGinley JL
Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
[TBL] [Abstract][Full Text] [Related]
5. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
6. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
8. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387
[TBL] [Abstract][Full Text] [Related]
9. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Gupta R; Norman RW; Murphy PR; Rittmaster RS; Too CK
J Urol; 2008 Jan; 179(1):147-51. PubMed ID: 17997435
[TBL] [Abstract][Full Text] [Related]
10. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M
Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
[TBL] [Abstract][Full Text] [Related]
11. Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells.
Lo S; King I; Alléra A; Klingmüller D
Toxicol In Vitro; 2007 Apr; 21(3):502-8. PubMed ID: 17218080
[TBL] [Abstract][Full Text] [Related]
12. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
13. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
14. Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats.
Sánchez P; Torres JM; Vílchez P; Del Moral RG; Ortega E
IUBMB Life; 2008 Jan; 60(1):68-72. PubMed ID: 18379994
[TBL] [Abstract][Full Text] [Related]
15. Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size.
Cabeza M; Zambrano A; Heuze I; Carrizales E; Palacios A; Segura T; Valencia N; Bratoeff E
Steroids; 2009 Oct; 74(10-11):793-802. PubMed ID: 19406144
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
17. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
18. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
Dolder CR
Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
[TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
